Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Nyxoah ( (NYXH) ) has issued an update.
On December 17, 2025, Nyxoah announced the commercial launch of its Genio hypoglossal neurostimulation system in the Netherlands, with the first implants successfully performed at OLVG West in Amsterdam and Zuyderland Hospital in Heerlen, underscoring growing European adoption of its battery-free, MRI-compatible OSA therapy. Separately, the company reported that on December 16, 2025 it amended its previously agreed €45 million amortizing senior unsecured convertible notes financing so that the investor receives an 8% subscription fee instead of an original issue discount, and on December 18, 2025 it issued the first €22.5 million tranche and paid roughly €1.8 million in fees, with a second €22.5 million tranche still subject to closing conditions; assuming completion, Nyxoah expects about €41.4 million in gross proceeds to support working capital and general corporate purposes, strengthening its cash runway as it accelerates commercial rollout of Genio in Europe and prepares for broader market expansion.
The most recent analyst rating on (NYXH) stock is a Hold with a EUR5.00 price target. To see the full list of analyst forecasts on Nyxoah stock, see the NYXH Stock Forecast page.
More about Nyxoah
Nyxoah SA is a Belgium-based medical technology company focused on developing and commercializing neuromodulation therapies for obstructive sleep apnea (OSA). Its lead product, the Genio system, is a patient-centric, leadless and battery-free hypoglossal nerve stimulation device designed as an alternative for patients who do not tolerate continuous positive airway pressure (CPAP). Genio has held a CE Mark in Europe since 2019, has expanded indications including Complete Concentric Collapse patients, and received U.S. FDA approval in August 2025 for a defined subset of adults with moderate to severe OSA, positioning Nyxoah as a differentiated player in the global sleep-disordered breathing market.
Average Trading Volume: 86,103
Current Market Cap: €182.2M
For an in-depth examination of NYXH stock, go to TipRanks’ Overview page.